Clinical correlations and prognostic relevance of Fn14 expression in breast carcinoma

Histology and Histopathology

Volumn 28, Issue 7, 2013, Pages 859-864

  Wang, Jian ^a   Liu, Yang ^a   Wei, Min Jie ^a   Mi, Xiao Yi ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Fn14; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

AGED; ARTICLE; BREAST TUMOR; CARCINOMA; CELL STRAIN MCF 7; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PHENOTYPE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MCF-7 CELLS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 84879773622     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Biswas D.K. and Iglehart J.D. (2006). Linkage between EGFR family receptors and nuclear factor kB (NF-ÎB) signaling in breast cancer. J. Cell Physiol. 209, 645-652.
2. Bombonati A. and Sgroi D.C. (2006). The molecular pathology of breast cancer progression. J. Pathol. 223, 307-317.
3. Brown S.A., Richards C.M., Hanscom H.N., Feng S.L. and Winkles J.A. (2003). The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-fB activation. Biochem. J. 371, 395-403.
4. Chorianopoulos E., Heger T., Lutz M., Frank D., Bea F., Katus H.A. and Frey N. (2010). FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res. Cardiol. 105, 301-313.
5. Donohue P.J., Richards C.M., Brown S.A., Hanscom H.N., Buschman J., Thangada S., Hla T., Williams M.S. and Winkles J.A. (2003). TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler. Thromb. Vasc. Biol. 23, 594-600.
6. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H. and Okumura K. (2002). Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 299, 488-493.
7. Jiang Q., Zhang H. and Zhang P. (2011). ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro. J. Exp. Clin. Cancer Res. 30, 60-71.
8. Michaelson J.S., Cho S., Browning B., Zheng T.S., Lincecum J.M., Wang M.Z., Hsu Y.M. and Burkly L.C. (2005). Tweak induces mammary epithelial branching morphogenesis. Oncogene 24, 2613-2624.
9. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R. and Massagué J. (2005). Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44-55.
10. Mustonen E., Säkkinen H., Tokola H., Isopoussu E., Aro J., Leskinen H., Ruskoaho H. and Rysä J. (2010). Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiologica 199, 11-22.
11. Pianetti S., Guo S., Kavanagh K.T. and Sonenshein G.E. (2002). Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 62, 652-655.
12. Polek T.C., Talpaz M., Darnay B.G. and Spivak-Kroizman T. (2003). TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR: Evidence for a second TWEAK receptor. J. Biol. Chem. 278, 32317-32323.
13. Press M.F., Sauter G., Bernstein L., Villalobos I.E., Mirlacher M., Zhou J.Y., Wardeh R., Li Y.T., Guzman R., Ma Y., Sullivan-Halley J., Santiago A., Park J.M., Riva A. and Slamon D.J. (2005). Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11, 6598-65607.
14. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. (1989). Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 244, 707-712.
15. Thompson E.W., Paik S., Brünner N., Sommers C.L., Zugmaier G., Clarke R., Shima T.B., Torri J., Donahue S., Lippman M.E. and Press M.F. (1992). Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell Physiol. 150, 534-544.
16. Tran N.L., McDonough W.S., Donohue P.J., Winkles J.A., Berens T.J., Ross K.R., Hoelzinger D.B., Beaudry C., Coons S.W. and Berens M.E. (2003). The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am. J. Pathol. 162, 1313-1321.
17. Tran N.L., McDonough W.S., Savitch B.A., Fortin S.P., Winkles J.A., Symons M., Nakada M., Cunliffe H.E., Hostetter G., Hoelzinger D.B., Rennert J.L., Michaelson J.S., Burkly L.C., Lipinski C.A., Loftus J.C., Mariani L. and Berens M.E. (2006). Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-vB and correlate with poor patient outcome. Cancer Res. 66, 9535-9542.
18. Wang S., Zhan M., Yin J., Abraham J.M., Mori Y., Sato F., Xu Y., Olaru A., Berki A.T., Li H., Schulmann K., Kan T., Hamilton J.P., Paun B., Yu M.M., Jin Z., Cheng Y., Ito T., Mantzur C., Greenwald B.D. and Meltzer S.J. (2006). Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 25, 3346-3356.
19. Watts G.S., Tran N.L., Berens M.E., Bhattacharyya A.K., Nelson M.A., Montgomery E.A. and Sampliner R.E. (2007). Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int. J. Cancer 121, 2132-2139.
20. Weinberg J.M. (2011). TWEAK-Fn14 as a mediator of acute kidney injury. Kidney Int. 79, 151-153
21. Willis A.L., Tran N.L., Chatigny J.M., Charlton N., Vu H., Brown S.A., Black M.A., McDonough W.S., Fortin S.P., Niska J.R., Winkles J.A. and Cunliffe H.E. (2008). The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol. Cancer Res. 6, 725-734.
22. Winkles J.A., Tran N.L., Brown S.A., Stains N., Cunliffe H.E. and Berens M.E. (2007). Role of TWEAK and Fn14 in tumor biology. Front Biosci. 12, 2761-2771.
23. Xiang L., Liu Z.H., Huan Q., Su P., Du G.J., Wang Y., Gao P. and Zhou G.Y. (2012). Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. Diagn. Pathol. 7, 32-38
24. Xu H., Okamoto A., Ichikawa J., Ando T., Tasaka K., Masuyama K., Ogawa H., Yagita H., Okumura K. and Nakao A. (2004). TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem. Biophys. Res. Commun. 318, 422-427
25. Xu W.H., Liu Z.B., Yang C., Qin W. and Shao Z.M. (2012). Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype. PLoS One 7(5), e37624.